CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing innovative treatment strategies for aggressive epithelial ovarian cancer, particularly targeting tumors with p53 mutations. It aims to evaluate the efficacy of a new drug strategy that inhibits a key protein involved in cancer aggressiveness and resistance to chemotherapy.
Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe.
The predominance of aggressive Type II tumours (comprised of high-grade serous, high-grade endometrioid, and undifferentiated carcinomas) and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate.
The preeminant molecular hallmark of Type II tumours is the near ubiquitous presence of p53 mutations (in >96% of patients).
Th…
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Leuven
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany, Berlin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Hamburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
MEDIZINISCHE UNIVERSITAET WIEN
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
